Citadel Advisors’s CARDIUM THERAPEUTICS INC NEW CXM Stock Holding History

Citadel Advisors’s Portfolio CXM Stock Details CXM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-2,924	Closed	-$4K	–	7068
2013 Q2	$4K	Buy	+2,924	New	+$5.26K	﹤0.01%	6377

Other funds holding CXM

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Canada Life Winnipeg, Manitoba, Canada $55.8B AUM 26.04% 1-Year Est. Return

Citadel Advisors's CXM Position: Q3 2013 in Review

Citadel Advisors sold out of CARDIUM THERAPEUTICS INC NEW (CXM) in Q3 2013, closing a stake of 2,924 shares — an estimated $4K sold.

Citadel Advisors first reported a position in CXM in Q2 2013 and held it in 1 quarter. The position peaked at $4K in Q2 2013. 8 funds tracked by Wall St. Rank hold CXM as of Q3 2013.

Citadel Advisors reported no remaining CARDIUM THERAPEUTICS INC NEW position as of Q3 2013 after selling out during the quarter.
Citadel Advisors sold 2,924 CARDIUM THERAPEUTICS INC NEW shares in Q3 2013, an estimated $4K.
Citadel Advisors first reported a position in CARDIUM THERAPEUTICS INC NEW in Q2 2013 and held it in 1 quarter.
Citadel Advisors's CARDIUM THERAPEUTICS INC NEW position peaked at $4K in Q2 2013.
8 funds tracked by Wall St. Rank held CARDIUM THERAPEUTICS INC NEW as of Q3 2013.

Based on Citadel Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.